Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory ...

While some brands have made efforts to create healthier alternatives, others continue to rely on low-quality ingredients that ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Vor Biopharma gains rights to autoimmune drug telitacicept, raises capital and names a new CEO in a major strategic reset.

Officials in Ruidoso, New Mexico will hold a press conference following the three deaths reported due to floods on Tuesday.

Warburg Pincus steht kurz vor der Übernahme einer Mehrheitsbeteiligung an der Uvex Group, dem Fürther Hersteller von ...

Equipped with a new CEO, Vor Bio is transitioning into an autoimmune player, leaving cell and gene therapy behind.

Fintel reports that on June 30, 2025, HC Wainwright & Co. upgraded their outlook for Vor Biopharma (NasdaqGS:VOR) from ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million in new funding.

Die Europäische Union könnte nach Einschätzung von Frankreichs Finanzminister Eric Lombard noch vor dem 9. Juli ein ...

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635 (c) (4) GlobeNewswire Jul 1, 2025, 8:00:00 PM Vor Bio Announces $175 Million Private Placement GlobeNewswire Jun 25, 2025, 8:50:16 PM ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...